Fig. 2.

Mean (± SEM) whole-brain time–activity curves (SUV) of (R)-[¹¹C]verapamil in wild-type (wt, n = 5, black circles), Mrp1^(−/−) (n = 4, beige diamonds), Bcrp1^(−/−) (n = 3, green triangles), Mdr1a/b^(−/−) (n = 3, red squares) and Mdr1a/b^(−/−)Bcrp1^(−/−) mice (n = 3, blue triangles) for scan 1 (A) and scan 2 (B). At 60 min after start of scan 1 tariquidar (15 mg/kg) was administered as an i.v. bolus, which is indicated by an arrow. Scan 2 was performed at 2 h after administration of tariquidar (see timeline on top of the figure). In panels C and D, mean (± SEM) brain-to-blood ratios of activity (K_b,brain) at 25 min after (R)-[¹¹C]verapamil injection are shown for different mouse types before (C) and after (D) tariquidar administration. Blood activity concentrations (SUV) measured at 25 min after (R)-[¹¹C]verapamil injection in separate groups of mice before and after tariquidar administration are shown in panels E and F, respectively. Significant differences are indicated by asterisk (*p < 0.05; ***p < 0.001).